Safety and efficacy of live attenuated, cold-adapted, influenza vaccine-trivalent

Immunology and Allergy Clinics of North America

Volumn 23, Issue 4, 2003, Pages 745-767

  Belshe, Robert B ^a   Mendelman, Paul M ^b  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MEDIMMUNE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; COLD ADAPTED LIVE ATTENUATED INFLUENZA VACCINE TRIVALENT; INACTIVATED VACCINE; INFLUENZA VACCINE; LIVE VACCINE; TRIPLE VACCINE; UNCLASSIFIED DRUG;

ADOLESCENT; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; FEVER; HUMAN; IMMUNOGENICITY; INFLUENZA; LOWER RESPIRATORY TRACT; NONHUMAN; NOSE CONGESTION; OTITIS MEDIA; PHYSICAL ACTIVITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; REVACCINATION; REVIEW; RHINORRHEA; SCHOOL CHILD; SORE THROAT; SYMPTOM; VIRUS STRAIN;

EID: 0346102606     PISSN: 08898561     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8561(03)00098-5     Document Type: Review

References (48)

1. Belshe RB, Gruber WC. Prevention of otitis media in children with live attenuated influenza vaccine given intranasally. Pediatr Infect Dis J 2000;19:S66-71.
2. Belshe RB, Mendelman PM, Treanor J, King J, Gruber WC, Piedra P, et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine in children. N Engl J Med 1998;338:11405-12.
3. Belshe RB, Gruber WC, Mendelman PM, Cho I, Reisinger K, Block SL, et al. Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J Pediatr 2000;136:168-75.
4. Belshe RB, Gruber WC, Mendelman PM, Harshvardhan BM, Mahmood K, Reisinger K, et al. Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent intranasal influenza virus vaccine. J Infect Dis 2000;181:1133-7.
5. Nichol KL, Mendelman PM, Mallon KP, Jackson LA, Gorse GJ, Belshe RB, et al. Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial. JAMA 1999;282:137-45.
6. Maassab HF. Biologic and immunologic characteristics of cold-adapted influenza virus. J Immunol 1969;102:728-32.
7. Donabedian AM, DeBorde DC, Maassab HF. Genetics of cold-adapted B/Ann Arbor/1/66 influenza virus reassortants: the acidic polymerase (PA) protein gene confers temperature sensitivity and attenuated virulence. Microb Pathog 1987;3:97-108.
8. Maassab HF, Heilman CA, Herlocher ML. Cold-adapted influenza viruses for use as live vaccines for man. Adv in Biotechnol Proces 1990;14:203-42.
9. Cox NJ, Maassab HF, Kendal AP. Comparative studies of wild-type and cold-mutant (temperature-sensitive) influenza viruses: nonrandom reassortment of genes during preparation of live virus vaccine candidates by recombination at 25° between recent H3N2 and H1N1 epidemic strains and cold-adapted A/Ann Arbor/6/10. Virology 1979;97:190-4.
10. Maassab HF, Kendal AP, Abrams GD, Monto AS. Evaluation of cold-recombinant influenza virus vaccine in ferrets. J Infect Dis 1982;146:780-90.
11. Hay AJ, Belshe RB, Anderson EL, Gorse GJ, Westblom TU. Influenza viruses. In: Belshe RB, editor. Textbook of human virology. St. Louis (MO): Mosby Year Book; 1991. p. 307-41.
12. Hoskins TW, Davies JR, Smith AJ, Miller CL, Allchin A. Assessment of inactivated influenza-A vaccine after three outbreaks of influenza A at Christ's Hospital. Lancet 1979;1:33-5.
13. Davies JR, Grilli EA. Natural or vaccine-induced antibody as a predictor of immunity in the face of natural challenge with influenza viruses. Epidemiol Infect 1989;102:325-33 [erratum Epidemiol Infect 1989;103:217].
14. Davies JR, Grilli EA. Natural or vaccine-induced antibody as a predictor of immunity in the face of natural challenge with influenza viruses. Epidemiol Infect 1989;102:325-33 [erratum Epidemiol Infect 1989;103:217].
15. Murphy BR, Clements ML. The systemic and mucosal immune response of humans to influenza A virus [review]. Cur Topics Microbiol Immunol 1989;146:107-16.
16. Gorse GJ, Belshe RB. Enhancement of anti-influenza A virus cytotoxicity following influenza A virus vaccination in older, chronically ill adults. J Clin Microbiol 1990;28:2539-50.
17. Treanor JJ, Kotloff K, Betts RF, Belshe R, Newman F, Iacuzio D, et al. Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses. Vaccine 2000;18:899-906.
18. Clover RD, Crawford S, Glezen WP, Taber LH, Matson CC, Couch RB. Comparison of heterotypic protection against influenza A/Taiwan/86 (H1N1) by attenuated and inactivated vaccines to A/Chile/83-like viruses. J Infect Dis 1991;163:300-4.
19. Potter CW. Determinants of Immunity to Influenza Infection in Man. Br Med Bull 1979;335:69-75.
20. National Institutes of Health. Specific immunity in influenza B - summary of influenza workshop III. J Infect Dis 1973;127:220-36.
21. Fox JP, Cooney MK, Hall CE, Hjordis MF. Influenza virus infections in Seattle families, 1975-1979. Am J Epidemiol 1982;116:228-42.
22. 2/Hong Kong influenza vaccine efficacy 14 months after immunization. JAMA 1971;217:1067-71.
23. Hoskins TW, Davies JR, Smith AJ, Allchin A, Miller CL, Pollock TM. Influenza at Christ's Hospital: March 1974. Lancet 1976;1:105-8.
24. King JC, Lagos R, Bernstein DI, Piedra PA, Kotloff K, Bryant M, et al. Safety and immunogenicity of low and high doses of trivalent live cold-adapted influenza vaccine administered intranasally as drops or spray to healthy children. J Infect Dis 1998;177:1394-7.
25. Bernstein DI, Yan L, Treanor J, Mendelman PM, Belshe R, Cold-Adapted, Trivalent, Influenza Vaccine Study Group. Effect of yearly vaccinations with live, attenuated, cold-adapted, trivalent, intranasal influenza vaccines on antibody responses in children. Pediatr Infect Dis J 2003;22:28-34.
26. Gruber WC, Belshe RB, King JC, Treanor JJ, Piedra PA, Wright PF, et al and Newman F for the National Institute of Allergy and Infectious Diseases Vaccine and Treatment Evaluation Program and the Wyeth-Ayerst ca Influenza Vaccine Investigators Group. Evaluation of live attenuated influenza vaccines in children 6-18 months of age: safety, immunogenicity, and efficacy. J Infect Dis 1996;173:1313-9.
27. Edwards KM, Dupont WD, Westrich MK, Plummer Jr WD, Palmer PS, Wright PF. A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease. J Infect Dis 1994;169:68-76.
28. Black S, Shinefield H, Hansen J, et al. Large scale safety study of FluMist in 9,689 children 1-17 years of age [abstract]. Presented at the 3rd International Pediatric Infectious Disease Conference, October 28-30, 2001, Monterey, CA.
29. Black S, Shinefield H, Hansen J, et al. Large scale safety study of FluMist in 9,689 children 1-17 years of age [abstract]. Presented at the 5th Annual Conference on Vaccine Research, May 6-8, 2002, Baltimore, MD.
30. Redding G, Walker RE, Hessel C, Viranat FS, Ayars GH, Bensch G, et al. Safety and tolerability of cold-adapted influenza virus vaccine in children and adolescents with asthma. Pediatr Infect Dis J 2002;21:44-8.
31. Jackson LA, Holmes SJ, Mendelman PM, et al. Safety of a trivalent live attenuated intranasal influenza vaccine, FluMist, administered in addition to parenteral trivalent inactivated influenza vaccine to seniors with chronic medical conditions. Vaccine 1999;17:1905-9.
32. Treasor JJ, Mattison HR, Dumyati G, et al. Protective efficacy of combined live intranasal and inactivated influenza A virus vaccines in the elderly. Ann Intern Med 1992;117:625-33.
33. Gorse GJ, O'Connor TZ, Young SL, Mendelman PM, Bradley SF, Nichol KL, et al. Efficacy trial of live, cold-adapted and inactivated influenza virus vaccines in older adults with chronic obstructive pulmonary disease: a VA cooperative study. Vaccine 2003;21:2133-44.
34. King Jr JC, Treanor J, Fast PE, Wolff M, Yan L, Iacuzio D, et al. Comparison of the safety, vaccine virus shedding, and immunogenicity of influenza virus vaccine, trivalent, types A and B, live cold-adapted, administered to human immunodeficiency virus (HIV)-infected and non-HIV-infected adults. J Infect Dis 2000;181:725-8.
35. King Jr JC, Fast PE, Zangwill KM, Weinberg GA, Wolff M, Yan L, et al. Safety, vaccine virus shedding and immunogenicity of trivalent, cold-adapted, live attenuated influenza vaccine administered to human immunodeficiency virus-infected and noninfected children. Pediatr Infect Dis J 2001;10:1124-31.
36. Cha T-A, Kao K, Zhao J, Fast PE, Mendelman PM, Arvin A. Genotypic stability of cold-adapted influenza virus vaccine in an efficacy clinical trial. J Clin Microbiol 2000;38:839-45.
37. Belshe RB, Van Voris LP. Cold-recombinant influenza A/California/10/78 (H1N1) virus vaccine (CR-37) in seronegative children: infectivity and efficacy against investigational challenge. J Infect Dis 1984;149:735-40.
38. Clements ML, Snyder MH, Sears SD, et al. Evaluation of the infectivity, immunogenicity, and efficacy of live cold-adapted influenza B/Ann Arbor/1/86 reassortant virus vaccine in adult volunteers. J Infect Dis 1990;161:869-77.
39. Couch RB, Quarles JM, Cate TR, et al. Clinical trials with live cold-reassortant influenza virus vaccines. In: Kendal AP, Patriarca PA, editors. Options for the control of influenza. New York: Alan R. Liss; 1986. p. 223-41.
40. Davenport FM, Hennessy AV, Minuse E, et al. Pilot studies on mono and bivalent live attenuated influenza virus vaccines. Proceedings of the Symposium on Live Influenza Vaccine. Zagreb, Yugoslavia: Yugoslav Academy of Science and Arts; 1971. p. 105-13.
41. Davenport FM, Hennessy AV, Maassab HF, et al. Pilot studies on recombinant cold-adapted live type A and B influenza virus vaccines. J Infect Dis 1977;136:17-25.
42. Moritz AJ, Kunz C, Hofman H, et al. Studies with a cold-recombinant A/Victoria/3/75 (H3N2) virus. II. Evaluation in adult volunteers. J Infect Dis 1980;142:857-60.
43. Reeve P, Gerendas B, Moritz A, et al. Studies in man with cold-recombinant influenza virus (H1N1) live vaccines. J Med Virol 1980;6:75-83.
44. Van Voorthuizen F, Jens D, Saes F. Characterization and clinical evaluation of live influenza A Vaccine prepared from a recombinant of the A/USSR/92/77 (H1N1) and the cold-adapted A/Ann Arbor/6/60 (H2N2) strains. Antiviral Res 1981;1:107-22.
45. Wright PF, Okabe N, McKee Jr KT, et al. Cold-adapted recombinant influenza A virus vaccines in seronegative young children. J Infect Dis 1982;146:71-9.
46. Wright PF, Johnson PR, Karzon DT. Clinical experience with live, attenuated vaccines in children. In: Kendal AP, Patriarca PA, editors. Options for the control of influenza. New York: Alan R. Liss; 1986. p. 243-53.
47. Vesikari T, Karvonen A, Korhonen T, Elelman K, Vainionpää R, Salmi A, et al. A randomized, double-blind, placebo-controlled trial of the safety, transmissibility and phenotypic stability of a live, attenuated, cold-adapted influenza virus vaccine (CAIV-T) in children attending day care [abstract G-450]. Presented at the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 22-25, 2001, Chicago, IL.
48. Harper SA, Fukuda K, Cox NJ, Bridges CB. Using live, attenuated influenza vaccine for prevention and control of influenza. Supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2003;52:1-8.